Artículos por temáticas

Alzheimer: A Decade of Drug Design. Why Molecular Topology can be an Extra Edge?

Zanni R, Garcia-Domenech R, Galvez-Llompart M, Galvez J.

Curr Neuropharmacol. 2018;16(6):849-864. doi: 10.2174/1570159X15666171129102042.

Revalidation of the neuroprotective effects of a United States patented polyherbal formulation on scopolamine induced learning and memory impairment in rats

Upadhyay P, Sadhu A, Singh PK, Agrawal A, Ilango K, Purohit S, Dubey GP.

Biomed Pharmacother. 2018 Jan;97:1046-1052. doi: 10.1016/j.biopha.2017.11.008. Epub 2017 Nov 9.

Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain

Hey JA, Kocis P, Hort J, Abushakra S, Power A, Vyhnálek M, Yu JY, Tolar M.

CNS Drugs. 2018 Sep;32(9):849-861. doi: 10.1007/s40263-018-0554-0.

Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer's Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors

Grossberg GT, Alva G, Hendrix S, Ellison N, Kane MC, Edwards J.

Alzheimer Dis Assoc Disord. 2018 Jul-Sep;32(3):173-178. doi: 10.1097/WAD.0000000000000261.

Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials

Atri A, Frölich L, Ballard C, Tariot PN, Molinuevo JL, Boneva N, Windfeld K, Raket LL, Cummings JL.

JAMA. 2018 Jan 9;319(2):130-142. doi: 10.1001/jama.2017.20373.

Comparison of the effects of selenomethionine and selenium-enriched yeast in the triple-transgenic mouse model of Alzheimer's disease

Zhang ZH , Wu QY , Chen C , Zheng R , Chen Y , Ni JZ , Song GL .

Food Funct. 2018 Jul 17;9(7):3965-3973. doi: 10.1039/c7fo02063e.

Toward a Rational Design to Regulate β-Amyloid Fibrillation for Alzheimer's Disease Treatment

Han X, He G.

ACS Chem Neurosci. 2018 Feb 21;9(2):198-210. doi: 10.1021/acschemneuro.7b00477. Epub 2018 Jan 3.

Qualitative analysis of the capacity to consent to treatment in patients with a chronic neurodegenerative disease: Alzheimer's disease / Analisi qualitativa sulla capacità a prestare consenso al trattamento in pazienti con malattie cronico degenerative neuropsicoorganiche: Demenza di Alzheimer

Carabellese F, Felthous AR, La Tegola D, Piazzolla G, Distaso S, Logroscino G, Leo A, Ventriglio A, Catanesi R.

Int J Soc Psychiatry. 2018 Feb;64(1):26-36. doi: 10.1177/0020764017739642. Epub 2017 Nov 28.

Developing a dementia-specific preference--based quality of life measure (AD-5D) in Australia: a valuation study protocol

Comans TA, Nguyen KH, Mulhern B, Corlis M, Li L, Welch A, Kurrle SE, Rowen D, Moyle W, Kularatna S, Ratcliffe J.

BMJ Open. 2018 Jan 21;8(1):e018996. doi: 10.1136/bmjopen-2017-018996.

Effects of creative expression therapy for older adults with mild cognitive impairment at risk of Alzheimer's disease: a randomized controlled clinical trial

Zhao J, Li H, Lin R, Wei Y, Yang A.

Clin Interv Aging. 2018 Jul 24;13:1313-1320. doi: 10.2147/CIA.S161861. eCollection 2018.

A double-blind placebo-controlled cross-over clinical trial of DONepezil In Posterior cortical atrophy due to underlying Alzheimer's Disease: DONIPAD study

Ridha BH, Crutch S, Cutler D, Frost C, Knight W, Barker S, Epie N, Warrington EK, Kukkastenvehmas R, Douglas J, Rossor MN.

Alzheimers Res Ther. 2018 May 1;10(1):44. doi: 10.1186/s13195-018-0363-1.

Oxidative Stress in Elderly with Different Cognitive Status: My Mind Project

Fattoretti P, Malavolta M, Fabbietti P, Papa R, Giacconi R, Costarelli L, Galeazzi R, Paoloni C, Postacchini D, Lattanzio F, Giuli C.

J Alzheimers Dis. 2018;63(4):1405-1414. doi: 10.3233/JAD-171117.

Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab

Liu E, Wang D, Sperling R, Salloway S, Fox NC, Blennow K, Scheltens P, Schmidt ME, Streffer J, Novak G, Einstein S, Booth K, Ketter N, Brashear HR; ELN115727-301/302 Investigator Group.

Neurology. 2018 Mar 6;90(10):e877-e886. doi: 10.1212/WNL.0000000000005060. Epub 2018 Feb 2.

Mechanistic comparison of current pharmacological treatments and novel phytochemicals to target amyloid peptides in Alzheimer's and neurodegenerative diseases

Ayyalasomayajula N, Suresh C.

Nutr Neurosci. 2018 Dec;21(10):682-694. doi: 10.1080/1028415X.2017.1345425. Epub 2017 Jul 6.

A comparative study of EPA-enriched ethanolamine plasmalogen and EPA-enriched phosphatidylethanolamine on Aβ(42) induced cognitive deficiency in a rat model of Alzheimer's disease

Che H , Li Q , Zhang T , Ding L , Zhang L , Shi H , Yanagita T , Xue C , Chang Y , Wang Y .

Food Funct. 2018 May 23;9(5):3008-3017. doi: 10.1039/c8fo00643a.